Loss of KMT2D accelerates hypertrophic chondrocyte differentiation and senescence by increasing mitochondrial ROS production

Abstract

Longitudinal bone growth occurs through endochondral ossification, which is accompanied by the differentiation of chondrocytes in the growth plate. Disruption in chondrocyte maturation can lead to skeletal growth abnormalities, such as those observed in Kabuki syndrome type 1 (KS1), a genetic disorder caused by heterozygous pathogenic variants in the KMT2D gene. KS1 patients exhibit postnatal growth deficiency, craniofacial hypoplasia, and skeletal deformities, yet the mechanisms underlying these phenotypic manifestations remain poorly understood. Our study investigated the effects of KMT2D deficiency on chondrocyte maturation and identified premature chondrocyte hypertrophy as a key driver of skeletal abnormalities in KS1. We previously observed reduced femur and tibia length in a KS1 mouse model, along with altered growth plate architecture, particularly affecting the heights of the proliferative and hypertrophic zones. Here, we show that KMT2D-deficient chondrocytes exhibit accelerated differentiation and early senescence upon exposure to supraphysiological oxygen levels (20% O2). These pathological changes were linked to increased mitochondrial reactive oxygen species (ROS) production likely caused by deficiencies in electron transport chain function, leading to oxidative stress and premature hypertrophy. Pharmacological ROS neutralization or hypoxic conditions mitigated these effects, restoring normal chondrocyte differentiation and preventing premature ossification. These findings demonstrate that KMT2D loss induces oxidative stress-driven chondrocyte hypertrophy, disrupting the balance of cartilage growth and ossification. Our study provides crucial mechanistic insights into KS1-associated skeletal abnormalities and suggests mitochondrial ROS regulation as a potential therapeutic avenue.